WELLESLEY, MA--(Marketwired - Oct 10, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, will be featured during the opening day activities at the Nanomanufacturing Summit 2013 October 15-17, 2013 at the University of Pennsylvania in Philadelphia.

Dr. Ellis-Behnke's keynote speech encompasses, "Nanomedicine: discovering, manufacturing and using new Molecular Medical Devices for immediate hemostasis." He will focus on how related new technology, including AC5™, should fundamentally alter the practice of medicine and surgery, as well as how material design at the nanoscale can provide desired product properties and characteristics.

Ellis-Behnke, comments, "The Nanomanufacturing Summit is a great opportunity for government, universities, industry and business to exchange emergent information on the current status of nanoscale products as well as offering insights into new commercial practices that introduce robust manufacturing techniques with an ability to actually make the leap from the research lab into medical practices across the nation and around the world." 

Dr. Ellis-Behnke was instrumental in discovering the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care faster and safer. He proposed the development and commercialization of what became Arch Therapeutics' flagship product candidate, now known as AC5™. Arch Therapeutics obtained the exclusive worldwide license on the relevant intellectual property, of which Dr. Ellis-Behnke is the lead inventor, from the Massachusetts Institute of Technology and focused on design and manufacturing at the nanoscale in order to bring AC5™ closer to commercialization. 

Dr. Ellis-Behnke continues, "Arch Therapeutics' work is of vital importance in this field, as they are instrumental in understanding how to translate these discoveries into commercially viable processes and products designed to fulfill areas of extraordinary medical need. For instance, Arch's focus on surgical bleeding is important because up to 50% of a surgeon's procedure time can be devoted to controlling bleeding with the currently available technology."

Arch Therapeutics CEO, Dr. Terrence Norchi commented, "Dr. Ellis-Behnke remains a cutting edge thinker in the nanomedicine realm. He brings an interdisciplinary approach to addressing challenges of interventional healthcare and healing." Dr. Norchi further commented, "Our collective focus on product design and build at the nanoscale is very important to Arch's approach to areas of significant medical need, starting with the mitigation of bleeding during surgery. The nanoscale world holds great promise for the future of medicine and for our products, in particular."

Additional details regarding Arch Therapeutics, Inc., its business, agreements and related matters are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission ("SEC"), and are available at the SEC's website at www.sec.gov. For more information, visit our website at www.archtherapeutics.com.

About Arch Therapeutics, Inc. (OTCQB: ARTH)
Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's goal is to develop and commercialize products based on our innovative technology platform that make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,

Terrence W. Norchi, MD.
Arch Therapeutics, Inc.

Contact Information:

ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com